These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8993544)

  • 61. Diminished hepatocellular proliferation in mice humanized for the nuclear receptor peroxisome proliferator-activated receptor alpha.
    Cheung C; Akiyama TE; Ward JM; Nicol CJ; Feigenbaum L; Vinson C; Gonzalez FJ
    Cancer Res; 2004 Jun; 64(11):3849-54. PubMed ID: 15172993
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine.
    Poirier H; Niot I; Monnot MC; Braissant O; Meunier-Durmort C; Costet P; Pineau T; Wahli W; Willson TM; Besnard P
    Biochem J; 2001 Apr; 355(Pt 2):481-8. PubMed ID: 11284737
    [TBL] [Abstract][Full Text] [Related]  

  • 63. PPAR-alpha: a key to the mechanism of hepatoprotection by clofibrate.
    Mehendale HM
    Toxicol Sci; 2000 Oct; 57(2):187-90. PubMed ID: 11006348
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver.
    Akbiyik F; Cinar K; Demirpence E; Ozsullu T; Tunca R; Haziroglu R; Yurdaydin C; Uzunalimoglu O; Bozkaya H
    Eur J Clin Invest; 2004 Jun; 34(6):429-35. PubMed ID: 15200495
    [TBL] [Abstract][Full Text] [Related]  

  • 65. A single amino acid change in the mouse peroxisome proliferator-activated receptor alpha alters transcriptional responses to peroxisome proliferators.
    Hsu MH; Palmer CN; Griffin KJ; Johnson EF
    Mol Pharmacol; 1995 Sep; 48(3):559-67. PubMed ID: 7565638
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Peroxisome proliferators and signal transduction.
    Bronfman M; Nuñez L; Orellana A; Burzio V; Hidalgo P
    Ann N Y Acad Sci; 1996 Dec; 804():403-12. PubMed ID: 8993559
    [No Abstract]   [Full Text] [Related]  

  • 67. Development of hepatocellular carcinomas and increased peroxisomal fatty acid beta-oxidation in rats fed [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (Wy-14,643) in the semipurified diet.
    Lalwani ND; Reddy MK; Qureshi SA; Reddy JK
    Carcinogenesis; 1981; 2(7):645-50. PubMed ID: 7273344
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Peroxisome proliferation and hepatotoxicity in rodents.
    Grasso P
    Biochem Soc Trans; 1985 Oct; 13(5):861-2. PubMed ID: 4065422
    [No Abstract]   [Full Text] [Related]  

  • 69. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.
    Reddy JK; Moody DE; Azarnoff DL; Tomarelli RM
    Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):51-7. PubMed ID: 851495
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Pleiotrophic peroxisome induction by hypolipidemic agents in primates and rodents].
    Stangl H; Kovacs W; Kopeky E; Nagl G; Kremser K
    Wien Klin Wochenschr; 1996; 108(2):40-4. PubMed ID: 8835431
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.
    Lemberger T; Desvergne B; Wahli W
    Annu Rev Cell Dev Biol; 1996; 12():335-63. PubMed ID: 8970730
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Receptor-mediated mechanisms of peroxisome proliferators.
    Green S
    Biochem Pharmacol; 1992 Feb; 43(3):393-401. PubMed ID: 1311577
    [No Abstract]   [Full Text] [Related]  

  • 73. Peroxisome proliferator activated receptors and stroke.
    Fruchart JC; Bordet R; Duriez P
    Curr Atheroscler Rep; 2003 Sep; 5(5):331-2. PubMed ID: 12911841
    [No Abstract]   [Full Text] [Related]  

  • 74. Nuclear receptor superfamily reunion. Keystone Symposium Nuclear Receptor Superfamily, Lake Tahoe, California, USA. 17-23 March 1996.
    Parker MG
    Trends Genet; 1996 Jul; 12(7):277-8. PubMed ID: 8763501
    [No Abstract]   [Full Text] [Related]  

  • 75. A gut check for PPARgamma.
    Wu GD; Lazar MA
    Gastroenterology; 1998 Nov; 115(5):1283-5. PubMed ID: 9797386
    [No Abstract]   [Full Text] [Related]  

  • 76. Hepatic peroxisome proliferation and oxidative stress.
    Lake BG; Gray TJ; Smith AG; Evans JG
    Biochem Soc Trans; 1990 Feb; 18(1):94-7. PubMed ID: 2185102
    [No Abstract]   [Full Text] [Related]  

  • 77. Review of the hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man.
    Cohen AJ; Grasso P
    Food Cosmet Toxicol; 1981 Oct; 19(5):585-605. PubMed ID: 7030887
    [No Abstract]   [Full Text] [Related]  

  • 78. Nuclear transcription factors: new opportunities for lipid lowering.
    Staels B
    Proc Nutr Soc; 2000 Aug; 59(3):433. PubMed ID: 10997667
    [No Abstract]   [Full Text] [Related]  

  • 79. Regulatory implications of peroxisome proliferation: an industrial perspective.
    Stott WT
    Ann N Y Acad Sci; 1996 Dec; 804():641-8. PubMed ID: 8993579
    [No Abstract]   [Full Text] [Related]  

  • 80. Saroglitazar suppresses the hepatocellular carcinoma induced by intraperitoneal injection of diethylnitrosamine in C57BL/6 mice fed on choline deficient, l-amino acid- defined, high-fat diet.
    Giri SR; Bhoi B; Trivedi C; Rath A; Rathod R; Sharma A; Ranvir R; Kadam S; Ingale K; Patel H; Nyska A; Jain MR
    BMC Cancer; 2023 Jan; 23(1):59. PubMed ID: 36650455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.